RAIDD Antibody
| Code | Size | Price |
|---|
| PSI-1115-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-1115-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
RAIDD Antibody: MRT34, RAIDD, Death domain-containing protein CRADD, Caspase and RIP adapter with death domain
Application Note:
RAIDD antibody can be used for detection of RAIDD by Western blot at 0.5 - 1 μg/mL. A 22 kDa band should be detected. Antibody can also be used for immunocytochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
RAIDD Antibody: Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain (DD)-containing receptors, TNFR1 and Fas. The death signals are transduced by a group of DD-containing adapter molecules. A novel cell death adapter was recently identified by two independent groups and designated RAIDD (RIP-associated ICH-1/CED-3-homologous protein with DD) and CRADD (caspase and RIP adapter with DD)1, RAIDD contains a DD and a CARD (for caspase recruitment domain) which interact with RIP and caspase, respectively, to transduce death signals1, 3. RAIDD is constitutively expressed in many tissues and mediates apoptosis caused by Fas and TNFR-1.
Background References:
- Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature 1997;385:86-89
- Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fernandes-Alnemri T, Alnemri ES. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997 57:615-619
- Hofmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 1997;22:155-156 (RD1299)
Buffer:
RAIDD Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Mouse: (78%)
Immunogen:
RAIDD antibody was raised against a 19 amino acid peptide near the center of human RAIDD.
The immunogen is located within amino acids 90 - 140 of RAIDD.
The immunogen is located within amino acids 90 - 140 of RAIDD.
NCBI Gene ID #:
8738
NCBI Official Name:
CASP2 and RIPK1 domain containing adaptor with death domain
NCBI Official Symbol:
CRADD
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
22 kDa
Protein Accession #:
AAB42217
Protein GI Number:
1785557
Purification:
RAIDD Antibody is affinity chromatography purified via peptide column.
Research Area:
Apoptosis,Cancer
Swissprot #:
P78560
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | RAIDD Peptide | PSI-1115P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|